Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, shared a post on X:
“Thorough, insightful review of PARP inhibitors in prostate cancer from Neeraj Agarwal, Huntsman Cancer Institute – monotherapy and rationale for combos. Important to test our patients for HRR alterations!”
Follow the latest ESMO 2025 news on OncoDaily.
